- Trial phase
- Approved
- Time to market
- Already approved and marketed since 2007 (smallpox) and 2024 (mpox).
- Why 4/10
- ACAM2000 is already FDA-approved and commercially marketed with no pending PDUFA date, AdComm, or pivotal readout in the next 12 months; the next catalysts are U.S. government contract option exercises and international regulatory decisions, which are not hard binary events, so the impact score is capped at 4 per the rubric.
ACAM2000 is an approved, revenue-generating product with no pending FDA binary catalyst. Watch for U.S. government contract option exercises (the 10-year ASPR deal has annual renewals) and further international approvals, which drive lumpy quarterly revenue. The Q3 2026 revenue miss and lowered guidance are the near-term headwind to watch.
Price Chart
Executive Summary
ACAM2000 is an FDA-approved live vaccinia virus vaccine for smallpox (since 2007) and mpox (expanded approval August 2024), manufactured by Emergent BioSolutions (NYSE: EBS). It is one of only two FDA-approved vaccines covering both diseases and is primarily sold to the U.S. government for the Strategic National Stockpile under a 10-year contract. In 2025, total projected ACAM2000 sales exceeded $120 million. However, the drug faces competition from Bavarian Nordic's JYNNEOS, a safer non-replicating vaccine preferred for routine mpox use. ACAM2000 revenue is lumpy and tied to government delivery timing: Q3 2026 Smallpox MCM revenues fell 68% year-over-year, contributing to a weak quarter that sent the stock down sharply. The drug is approved and commercialized with no pending FDA binary catalyst, making it a steady but unpredictable revenue contributor within Emergent's broader biodefense portfolio.
How It Works
ACAM2000 is a live vaccine made from vaccinia virus, a close relative of the smallpox and mpox viruses. It is administered by scratching the skin with a special two-pronged needle (scarification), which triggers the immune system to produce protective antibodies. Because it uses a live, replicating virus, it generates strong immunity but carries a higher risk of side effects than non-replicating vaccines.
Trial Status
ACAM2000 was FDA-approved in August 2007 for smallpox prophylaxis and received supplemental approval in August 2024 for mpox prevention. It is manufactured and supplied to the U.S. Strategic National Stockpile under a long-term government contract. International approvals were obtained in Singapore and Saudi Arabia in 2026.
The Two-Sided Case
Upcoming Catalysts
- U.S. government contract option year renewals under the 10-year ASPR agreement (annual exercises, next due in 2027)
- Potential additional international regulatory approvals for smallpox and mpox indications
- Quarterly revenue reports reflecting ACAM2000 delivery timing to the U.S. government
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Emergent BioSolutions Inc. 8-K EBS ·Originating report